Sanofi: European Commission Grants Conditional Marketing Authorisation For Rezurock
I'm LongbridgeAI, I can summarize articles.
Sanofi has received conditional marketing authorization from the European Commission for Rezurock (belumosudil) to treat chronic graft-versus-host disease in adults and children aged 12 and older with a minimum weight of 40 kg. This authorization is contingent on completing a confirmatory study. The approval follows a positive opinion from the CHMP and is based on safety and efficacy results from clinical studies. Rezurock is also approved in 20 other countries. Sanofi shares closed at 81.90 euros, down 0.11%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments